Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
Dean Follmann(National Institute of Allergy and Infectious Diseases), Lindsey R. Baden(Brigham and Women's Hospital), Karen L. Kotloff(University of Maryland, Baltimore), Hana M. El Sahly(Baylor College of Medicine), Michaël Desjardins(Centre Hospitalier de l’Université de Montréal), Holly Janes(Fred Hutch Cancer Center), Olive D. Buhule(National Institutes of Health), Jacqueline M. Miller(Moderna Therapeutics (United States)), Lawrence Corey(Fred Hutch Cancer Center), Kristen Marks(Cornell University), Kathleen M. Neuzil(Center for Global Development), Bethany Girard(Moderna Therapeutics (United States))
Cited by 138
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet Infectious Diseases|2017|1.4k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1990|1.3k